Affilogic
Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, collaborating with industry leaders worldwide. They focus on innovative nanotechnology solutions for therapeutic applications, including oncology, immunology, and brain delivery, leveraging their proprietary Nanofitin platform and strong intellectual property portfolio.
Industries
Nr. of Employees
small (1-50)
Affilogic
24 rue de la rainière, 44 300 Nantes, France
Patents
Products
Oral anti-TNFα therapeutic program (IBD)
Preclinical program developing orally deliverable protein scaffold therapeutics targeting TNF-α for local treatment of inflammatory bowel disease; advanced through a multi-partner FP7 consortium and pursued in ongoing preclinical development.
Affinity chromatography vaccine purification platform (DiViNe)
Ligand-based affinity chromatography approach validated in a multi-partner EU project to improve vaccine purification yields and purity (demonstrated on glycoconjugate vaccines and CRM197-targeted ligands).
Brain-delivery enabled therapeutic programs (BBB shuttle)
Preclinical brain-shuttle delivery programs using transferrin-receptor-targeting modules to transport fused therapeutic payloads across the blood–brain barrier; developed in collaboration with external partners toward IND-stage candidates.
Inhaled antiviral feasibility program (spray-dried pulmonary formulation)
Feasibility demonstration of spray-dried powder formulation of small affinity scaffolds for pulmonary delivery, showing retained activity and acceptable fine particle fraction when delivered via a single-dose dry powder inhaler.
Oral anti-TNFα therapeutic program (IBD)
Preclinical program developing orally deliverable protein scaffold therapeutics targeting TNF-α for local treatment of inflammatory bowel disease; advanced through a multi-partner FP7 consortium and pursued in ongoing preclinical development.
Affinity chromatography vaccine purification platform (DiViNe)
Ligand-based affinity chromatography approach validated in a multi-partner EU project to improve vaccine purification yields and purity (demonstrated on glycoconjugate vaccines and CRM197-targeted ligands).
Brain-delivery enabled therapeutic programs (BBB shuttle)
Preclinical brain-shuttle delivery programs using transferrin-receptor-targeting modules to transport fused therapeutic payloads across the blood–brain barrier; developed in collaboration with external partners toward IND-stage candidates.
Inhaled antiviral feasibility program (spray-dried pulmonary formulation)
Feasibility demonstration of spray-dried powder formulation of small affinity scaffolds for pulmonary delivery, showing retained activity and acceptable fine particle fraction when delivered via a single-dose dry powder inhaler.
Services
Targeted discovery and engineering of small protein binders for partner-nominated targets using a proprietary selection process; delivered as exclusive or non-exclusive collaborations.
Design and manufacture of multispecific multimers, antibody-fusion constructs and site-selective conjugates (genetic fusion, cysteine insertion, click chemistry) to attach payloads or additional targeting modules.
Discovery of specific capture ligands and their incorporation into chromatography media for affinity-based downstream purification of biologics and vaccines (including pilot-scale validation).
Feasibility and formulation work for pulmonary (spray-dried dry powder) and oral delivery of stable small protein scaffolds, including compatibility testing with inhaler devices and gastrointestinal stability assessments.
In vivo biodistribution, pharmacokinetics and efficacy studies in animal models, and development of radiolabeled tracers for PET imaging with rapid clearance profiles.
Targeted discovery and engineering of small protein binders for partner-nominated targets using a proprietary selection process; delivered as exclusive or non-exclusive collaborations.
Design and manufacture of multispecific multimers, antibody-fusion constructs and site-selective conjugates (genetic fusion, cysteine insertion, click chemistry) to attach payloads or additional targeting modules.
Discovery of specific capture ligands and their incorporation into chromatography media for affinity-based downstream purification of biologics and vaccines (including pilot-scale validation).
Feasibility and formulation work for pulmonary (spray-dried dry powder) and oral delivery of stable small protein scaffolds, including compatibility testing with inhaler devices and gastrointestinal stability assessments.
In vivo biodistribution, pharmacokinetics and efficacy studies in animal models, and development of radiolabeled tracers for PET imaging with rapid clearance profiles.
Expertise Areas
- Alternative protein scaffold discovery
- Multispecific biologics engineering
- Bioconjugation and site-selective chemistry
- Affinity ligand development and downstream purification
Key Technologies
- Small engineered protein scaffolds (≈7 kDa)
- Multispecific/multivalent fusion constructs
- Genetic fusion and click-chemistry conjugation
- Albumin-binding half-life extension modules
News & Updates
Affilogic will attend BIO International 2025 in Boston – USA from June 16-19, 2025.
Affilogic will attend ASCO 2025 in Chicago – USA from May 30 to June 3, 2025.
Affilogic will attend TIDES USA 2025 in San Diego – USA from May 19-22, 2025.
Affilogic presented Nanofitins® as effective vectors for nanoparticles and as antibody alternatives at the European Nanomedicine event in San Sebastian, 2014.
Affilogic showcased Nanofitins® for vaccine purification and development at the World Vaccines Congress in Barcelona, 2016.
Development of multispecific assemblies of Nanofitins with anti-tumor activities, and their application in modulating tumor microenvironment, presented at various conferences including PEGS Europe 2020.
Affilogic will attend BIO International 2025 in Boston – USA from June 16-19, 2025.
Affilogic will attend ASCO 2025 in Chicago – USA from May 30 to June 3, 2025.
Affilogic will attend TIDES USA 2025 in San Diego – USA from May 19-22, 2025.
Affilogic presented Nanofitins® as effective vectors for nanoparticles and as antibody alternatives at the European Nanomedicine event in San Sebastian, 2014.
Affilogic showcased Nanofitins® for vaccine purification and development at the World Vaccines Congress in Barcelona, 2016.
Development of multispecific assemblies of Nanofitins with anti-tumor activities, and their application in modulating tumor microenvironment, presented at various conferences including PEGS Europe 2020.